Table 1.
Demographic and clinical data about non-obstetric surgery.
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | |
|---|---|---|---|---|---|---|
| Age (years) | 37 | 22 | 39 | 32 | 36 | 21 |
| BMI (kg.m-2) | 22.8 | 27.9 | 25.3 | 22.7 | 20.1 | 27.5 |
| ASA-PS | II | II | II | II | II | II |
| Comorbidities | Crohn disease | Hypothyroidism | ||||
| Gestational age (weeks) at the time of surgery | 8 | 22 | 24 | 10 | 18 | 15 |
| Diagnosis | Appendicitis | Appendicitis | Breast Abscess | Ovarian torsion | Appendicitis | Appendicitis |
| Surgery | Laparoscopy | Laparoscopy | Surgical Drainage | Laparoscopy | Laparoscopy | Laparoscopy |
| Duration of surgery (minutes) | 65 | 50 | 25 | 50 | 40 | 83 |
| Dose of Rocuronium (mg.kg-1) | 0.6 | 0.7 | 0.9 | 0.9 | 1.0 | 1.1 |
| Dose of Sugammadex (mg.kg-1)a | 3.2 | 0.7 | 3.7 | 3.4 | 3.4 | 2.0 |
| Adverse event during surgery | None | None | None | None | None | None |
ASA-PS, The American Society of Anesthesiologists Physical Status.
a
Dose of sugammadex: 3-4 mg.kg-1 if TOF = 0 and PTC ≥ 1; 1-2 mg.kg-1 if TOF > 2; 0-1 mg.kg-1 if T4/T1 ≥ 0,9 (prevention of residual neuromuscular blockade) based on Groudine SB, Soto R, Lien C, Drover D, Roberts K. A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg. 2007;104:555-62.